Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Tumor budding - a potential biomarker in low grade salivary gland carcinomas?

View through CrossRef
BackgroundLow-grade salivary gland carcinoma is regularly treated with surgical therapy of the salivary gland without elective neck dissection in T1/2 carcinomas, either alone or with adjuvant radiation therapy. However, occult metastasis and locoregional recurrence influence therapy and outcome. Tumor budding is an emerging prognostic pathological factor in many carcinomas, but has not yet been adequately considered in salivary gland carcinomas.MethodsWe conducted a retrospective single-center study of 64 patients diagnosed with low-grade carcinoma of the major salivary glands treated between 2003 and 2017. Pathological risk factors and TNM classification were thoroughly assessed for each case. All hematoxylin and eosin (HE)-stained histological specimens underwent careful examination, and tumor budding was identified following the guidelines set forth by the International Tumor Budding Consensus Conference in 2016.ResultsTumor budding was not statistically significant concerning 5-year survival rate (5-YSR) (p=0.969) and mean overall survival (log-rank p=0.315). Whereas 5-year disease-free survival rate (5-YDFSR) was 87% in the low tumor budding group and 61.1% in the intermediate and high tumor budding group (p=0.021). Mean disease-free survival accounted for 100.2 months (CI: 88.6;111.9) in the low budding score group and 58.7 months (CI: 42.8;74.6) in the other group (log-rank p=0.032). Notably, pT1/2 showed significantly lower tumor buds than pT3/4 stages (2.43 tumor buds/0.785 mm2 vs. 4.19 tumor buds/0.785 mm2, p=0.034). Similar findings were noted comparing nodal-positive and nodal-negative patients, as well as patients with and without lymphovascular invasion and perineural invasion (each p<0.05).ConclusionsTumor budding might be used as an additional prognostic factor for recurrence in low-grade salivary gland carcinoma, seemingly associated with a higher nodal metastasis rate and advanced tumor stages and a worse 5-YDFSR. Consequently, the evaluation of tumor budding in resection specimens of low-grade salivary gland tumor may prove valuable in decision-making for neck dissection and follow-up strategy.
Title: Tumor budding - a potential biomarker in low grade salivary gland carcinomas?
Description:
BackgroundLow-grade salivary gland carcinoma is regularly treated with surgical therapy of the salivary gland without elective neck dissection in T1/2 carcinomas, either alone or with adjuvant radiation therapy.
However, occult metastasis and locoregional recurrence influence therapy and outcome.
Tumor budding is an emerging prognostic pathological factor in many carcinomas, but has not yet been adequately considered in salivary gland carcinomas.
MethodsWe conducted a retrospective single-center study of 64 patients diagnosed with low-grade carcinoma of the major salivary glands treated between 2003 and 2017.
Pathological risk factors and TNM classification were thoroughly assessed for each case.
All hematoxylin and eosin (HE)-stained histological specimens underwent careful examination, and tumor budding was identified following the guidelines set forth by the International Tumor Budding Consensus Conference in 2016.
ResultsTumor budding was not statistically significant concerning 5-year survival rate (5-YSR) (p=0.
969) and mean overall survival (log-rank p=0.
315).
Whereas 5-year disease-free survival rate (5-YDFSR) was 87% in the low tumor budding group and 61.
1% in the intermediate and high tumor budding group (p=0.
021).
Mean disease-free survival accounted for 100.
2 months (CI: 88.
6;111.
9) in the low budding score group and 58.
7 months (CI: 42.
8;74.
6) in the other group (log-rank p=0.
032).
Notably, pT1/2 showed significantly lower tumor buds than pT3/4 stages (2.
43 tumor buds/0.
785 mm2 vs.
4.
19 tumor buds/0.
785 mm2, p=0.
034).
Similar findings were noted comparing nodal-positive and nodal-negative patients, as well as patients with and without lymphovascular invasion and perineural invasion (each p<0.
05).
ConclusionsTumor budding might be used as an additional prognostic factor for recurrence in low-grade salivary gland carcinoma, seemingly associated with a higher nodal metastasis rate and advanced tumor stages and a worse 5-YDFSR.
Consequently, the evaluation of tumor budding in resection specimens of low-grade salivary gland tumor may prove valuable in decision-making for neck dissection and follow-up strategy.

Related Results

Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract Introduction Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...
Epithelial-Myoepithelial Carcinoma of Salivary Glands: A Tertiary Center Experience
Epithelial-Myoepithelial Carcinoma of Salivary Glands: A Tertiary Center Experience
Abstract Introduction Epithelial-myoepithelial carcinoma (EMC) is a rare, biphasic malignant tumor affecting the salivary glands. It represents less than 1% of all salivary gland t...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
SURGICAL APPROACH AND OUTCOMES IN SALIVARY GLAND SWELLING
SURGICAL APPROACH AND OUTCOMES IN SALIVARY GLAND SWELLING
Introduction: Salivary gland tumours are rare tumours and majority of these are benign and about 20% are malignant. The incidence of salivary gland cancers ranges from 0.5 to 2 per...
The role of the P2X7 nucleotide receptor in salivary gland inflammation
The role of the P2X7 nucleotide receptor in salivary gland inflammation
Salivary gland inflammation is a hallmark of Sjogren's syndrome (SS), a common autoimmune disease characterized by lymphocytic infiltration and the consequent impairment of the sal...
Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
BACKGROUND: Risk factors, including lymphatic, vascular, and perineural invasion, are considered indications for adjuvant treatment in stage II colon cancer. However, t...
Prognostic Impact of Tumor Budding on Moroccan Gastric Cancer Patients
Prognostic Impact of Tumor Budding on Moroccan Gastric Cancer Patients
Background: Tumor budding (TB) has been defined as an independent prognostic factor in many carcinomas like colon adenocarcinoma, but its prognostic impact on g...

Back to Top